title: [Preoperative chemotherapy of nephroblastoma. Preliminary results of the SIOP-9/GPO therapy study].
abstract: The therapeutic strategy of the SIOP-9 study includes pre-operative chemotherapy for all patients with nephroblastoma diagnosed by imaging methods aged between 0.5 and 16 years. By pre-operative chemotherapy the rate of radical resectable tumors should be increased and thereby the intensity of postoperative therapy, in particular of radiotherapy, diminished. Patients with nephroblastoma stage I-III were in case of tumorresponse randomised in either a 4 weeks or 8 weeks arm of pre-operative treatment with ACT D and VCR. The question was, if a prolongation of pre-operative chemotherapy could increase the relative part of stage I. Between 1/1/89 and 6/30/91 from 49 oncologic centres of former western Germany 188 patients were registered in the SIOP-9/GPO. From the stage I-III patients between 0.5 and 16 years 80.1% were pretreated with cytostatic agents. Only 53.9% of the patients with tumorresponse were randomised. The relative frequency of intraoperative ruptures was with 3% lower in the group of pretreated patients than in the primary operated (15.3%). The stage distribution for all Wilms' tumor patients showed a prevalence of stage I with 43.3% (after pre-operative treatment 59%; after primary operation 28%). Abdominal radiotherapy was performed in 22.4%. The event-free survival rate of all nephroblastoma lay at 85% 3 years after diagnosis (stage I standard 96%; unfavorable histology all stages 45%). 7.3% of the patients developed a hepatopathy under treatment and 7.8% even a VOD according to the criteria of McDonald.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Kinderklinik, Universität Heidelberg.
authors.forename: R
authors.initials: R
authors.lastname: Ludwig
authors.forename: A
authors.initials: A
authors.lastname: Weirich
authors.forename: R
authors.initials: R
authors.lastname: Pötter
authors.forename: D
authors.initials: D
authors.lastname: Harms
authors.forename: D
authors.initials: D
authors.lastname: Bürger
authors.forename: J
authors.initials: J
authors.lastname: Michaelis
authors.forename: R
authors.initials: R
authors.lastname: Erttmann
authors.forename: P
authors.initials: P
authors.lastname: Weinel
authors.forename: R J
authors.initials: RJ
authors.lastname: Haas
authors.forename: J
authors.initials: J
authors.lastname: Ritter
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003609:Dactinomycin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007223:Infant; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D009367:Neoplasm Staging; D009392:Nephrectomy; D014750:Vincristine / Q000008:administration & dosage; D009396:Wilms Tumor / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin
vernacular_title: Präoperative Chemotherapie des Nephroblastoms. Vorläufige Ergebnisse der Therapiestudie SIOP-9/GPO.